and will decide whether it should withdraw from the agreement and take other appropriate action or make final the agreement's proposed order.

This matter concerns advertising, packaging, labeling and promotional practices related to the sale of optical drives that read information on compact disc read-only memory discs (''CD–ROM drives''). The Commission's complaint charges that respondent misrepresented that its CD–ROM drives were all or virtually all made in the United States when, in truth and in fact, its CD–ROM drives were assembled in the United States of primarily imported parts. In addition, the complaint charges that respondent misrepresented that CD–ROM drives that were made in China of primarily non-U.S. parts were all or virtually all made in the United States.

The proposed consent order contains a provision that is designed to remedy the charges and to prevent the respondent from engaging in similar acts and practices in the future. Part I of the proposed order prohibits the respondent from misrepresenting the extent to which any CD–ROM drive is made in the United States. The proposed order would allow respondent to represent that a CD–ROM drive is made in the United States so long as all, or virtually all, of the component parts of the CD–ROM drive are made in the United States and all, or virtually all, of the labor in manufacturing the CD–ROM drive is performed in the United States.

Part II of the proposed order requires the respondent to maintain materials relied upon in disseminating any representation covered by the order. Part III of the proposed order requires the respondent to distribute copies of the order to certain company officials and employees. Part IV of the proposed order requires the respondent to notify the Commission of any change in the corporation that may affect compliance obligations under the order. Part V of the proposed order requires the respondent to file one or more compliance reports. Part VI of the proposed order is a provision whereby the order, absent certain circumstances, terminates twenty years from the date of issuance.

The purpose of this analysis is to facilitate public comment on the proposed consent order. It is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way their terms.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 99–1660 Filed 1–25–99; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0747]

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Customer/Partner Satisfaction Surveys; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of December 24, 1998 (63 FR 71294). The document announced that a proposed collection of information had been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995. The document was published with an incorrect docket number. This document corrects that error.

DATES: JANUARY 26, 1999.

FOR FURTHER INFORMATION CONTACT: Silvia R. Fasce, Office of Policy (HF–27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2994.

SUPPLEMENTARY INFORMATION: In FR Doc. 98–34111, appearing on page 71294 in the **Federal Register** of Thursday, December 24, 1998, the following correction is made:

1. On page 71294, in the first column, in the third line, ''[Docket No. 97N–0260]'' is corrected to read ''[Docket No. 98N–0747]''.

Dated: January 20, 1999.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 99–1711 Filed 1–25–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Pharmacy Compounding Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Pharmacy Compounding Advisory Committee which is scheduled for February 4 and 5, 1999. This meeting was announced in the **Federal Register** of January 6, 1999 (64 FR 886). The amendment is being made to reflect a change in the *Procedure* portion of the meeting notice. There are no other changes. This amendment will be announced at the beginning of the open portion of the meeting.

FOR FURTHER INFORMATION CONTACT: Igor Cerny or Tony Slater, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8183 (301–443–0572 in the Washington, DC area), code 12440.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of January 6, 1999 (64 FR 886), FDA announced that a meeting of the Pharmacy Compounding Advisory Committee would be held on February 4 and 5, 1999. This amendment is being made to reschedule the time allotted for oral presentations from the public.

On page 887, in the first column, the *Procedure* portion of this meeting notice is amended to read as follows:

Procedure: Interested persons may present data, information or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 29, 1999. Oral presentations from the public will be scheduled on February 4, 1999, between approximately 11 a.m. and 12 m. for: Mild silver protein, 4-aminopyridine, and 3,4-diaminopyridine, and between approximately 3 p.m. and 4 p.m. for: Hydrazine; and on February 5, 1999, between approximately 10 a.m. and 11 a.m. for: Dinitrochlorobenzene, diphenylcyclopropenone, and squaric acid dibutyl ester, and between approximately 3 p.m. and 4 p.m. for: Pentylenetetrazole, cyclandelate, and betahistine dihydrochloride. Time allotted for each presentation may be